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Abstract
House-dust mite (HDM) induced allergic rhinitis (AR) is a chronic condition
associated with rhinorrhea, nasal obstruction, nasal pruritus and sneezing. The current
mainstay of treatment is intranasal corticosteroids, which have shown variable
degrees of symptom control among patients. Immunotherapy works to increase
peripheral immune tolerance by administration of the allergen itself. This study
examined multiple randomized controlled trials to determine if sublingual
immunotherapy (SLIT) is a viable treatment option for allergic rhinitis.

Introduction
• Allergic rhinitis affects approximately 10-30% of adults and 40% of children,
with an estimated 60 million people suffering from the condition in the United
States.
• The presence of allergic rhinitis significantly affects a person’s quality of life,
contributing to issues like missed time at work or school, poor performance in
daily activities, and lack of sleep. Total economic toll has been roughly $6 billion
annually in the United States through direct and indirect costs of therapy and
occupational burden.
• Not all patients experience equivalent resolutions of symptoms on intranasal
corticosteroids and chronic use is required to achieve continued relief.
• Immunotherapy not only has the potential to decrease acute symptoms of allergic
rhinitis, but is also the only treatment with disease-modifying potential with longterm use.

Discussion

Literature search was performed in April 2020
Sources
Search
Terms
Inclusion
Criteria
Exclusion
Criteria

• Pubmed
• Clinical Key
“Immunotherapy” AND “allergic rhinitis” AND
“dust-mite” AND “sublingual”
• Published in the last 5 years (2015-2020)
• Human clinical trials
• Published in peer reviewed journal
• Systematic reviews or meta-analyses
• Clinical trials involving animals

Results
The evidence compiled through five randomized controlled trials
showed statistically significant symptom improvement in patients
treated with SLIT in comparison to a placebo. Total combined rhinitis
scores measured in three studies showed a reduction of greater than 15%
in active groups. Total symptom scores showed a significant decrease in
all studies analyzed. There were mixed significant and non-significant
results in the measurement of medication scores after SLIT. Quality of
life surveys showed improvement in active groups and the safety profile
was favorable in all studies.
Table 1. Comparison of Results
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Figure 1. Pathophysiology of Allergic Rhinitis. Allergic rhinitis is an IgE
antibody-mediated hypersensitivity reaction typically occurring after exposure to a
specific allergen. Allergen exposure triggers degranulation in mast cells, basophils
and eosinophils. Degranulation results in the release of cytokines, histamines, and
chemotactic factors. The release of these factors results in symptoms like
rhinorrhea, nasal obstruction, nasal pruritus, and sneezing. The immune system has
an intricate memory allowing a similar response to occur with subsequent exposure
to identical or similar allergens.
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placebo-controlled

1 year

12 SQ or
placebo

TCRS, DSS, DMS,
QOL

Okamoto
(2018)

Randomized,
placebo-controlled

1 year

300 IR or
placebo

AASS, RTSS, ARTSS;
ARMS, ISS,

10,000 JAU,
20,000 JAU or
placebo

TCRS, rhinitis
symptoms, MS, QOL,
symptom free days,
symptom severe days

Randomized,
placebo-controlled

1482

438

946

≥ 12

5-16

12-64

1 year

KEY
SQ = Standardized quantity; JAU = Japanese Allergy Units; TCRS = total combined rhinitis score; MS = medication score; QOL = quality of
life; NSS = nasal symptom score; TNSS = total nasal symptom score, ACS = allergic conjunctivitis score; DSS = daily symptom score; DMS =
daily medication score; AASS = average adjusted symptom score; RTSS = Rhinitis total symptom score; ARTSS; average rhinitis total symptom
score; ARMS = average rescue medication score; individual symptom score
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Overall, the study designs were similar in that they all used randomized
double-blind placebo-controlled trials, which contributed to the validity of the
studies. However, variable dosing and outcome measurements make
comparison difficult and reveal the need for standardization in this field.
Extension of the one-year duration of intervention should be considered to
determine the long-term effects of SLIT.
Table 2. Comparison of Study Designs

Categories
A = Adequate
M = Marginal
I = Inadequate

Statistical power
A = sample size > 400
M = sample size > 100
I = sample size <100

Timeline
A = well defined timeline (i.e.
dosing up regulation, follow up
and data collection outlined)
I = no defined timeline

Conclusion
SLIT should be considered as an alternative or adjunct in the treatment of
HDM-induced AR. SLIT has shown statistically significant symptomatic relief
and a favorable safety profile. However, further research is required before
SLIT can be recommended in place of the current standard of care. Costbenefit analysis and more long-term studies are necessary for better assessment
of where SLIT belongs on the treatment continuum.

